Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the United States, following approval from the U.S. Food and Drug Administration (USFDA). The product is the generic equivalent of Extra-Strength Pataday® (of Novartis AG) Once-Daily Relief, a leading over-the-counter antihistamine eye drop.
The newly launched formulation is indicated for the temporary relief of itchy eyes caused by common allergens such as pollen, ragweed, grass, animal hair, and dander. With a once-daily dosing regimen, the 0.7% strength offers consumers a convenient option for managing allergy-related eye symptoms.
“This launch strengthens our OTC eye-care portfolio, which already includes Olopatadine Hydrochloride Ophthalmic Solution USP in 0.2% and 0.1% strengths,” said Milan Kalawadia, CEO, North America Generics, Dr. Reddy’s Laboratories, Inc. “Being first to market reflects our strong development and commercialization capabilities in delivering high-quality store-brand equivalents in the U.S. OTC space. We look forward to expanding our partnerships with retail customers through this addition.”
According to NielsenIQ data, the Pataday® brand recorded U.S. sales of approximately USD 69.9 million for the 52-week period ending December 27, 2025, highlighting the commercial opportunity in the allergy eye-care segment.
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is supplied in a 2.5 mL bottle and will be available through major retail and pharmacy channels across the U.S.
